Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Capex-to-Revenue : 0.01 (As of Mar. 2024)

Tianjin Pharmaceutical Da Ren Tang Group Capex-to-Revenue Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Capex-to-Revenue		Get a 7-Day Free Trial					0.03	0.03	0.02	0.01	0.02

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial															0.02	0.01	0.01	0.02	0.01

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue falls into.

Tianjin Pharmaceutical Da Ren Tang Group Capex-to-Revenue Calculation

Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group  (SHSE:600329) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Tianjin Pharmaceutical Da Ren Tang Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description